[{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Partnership","leadProduct":"Menaquinone-7","moa":"||Pregnane X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SunWay Biotech \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"SunWay Biotech \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Menaquinone-7","moa":"||Pregnane X receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"NattoPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"NattoPharma \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"NattoPharma \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Aristotle University Of Thessaloniki","sponsor":"NattoPharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Menaquinone-7","moa":"||Pregnane X receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aristotle University Of Thessaloniki","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aristotle University Of Thessaloniki \/ NattoPharma","highestDevelopmentStatusID":"1","companyTruncated":"Aristotle University Of Thessaloniki \/ NattoPharma"}]

Find Clinical Drug Pipeline Developments & Deals for Menaquinone-7

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The partnership aims to launch SunWay's inaugural product, MenaQ7® Metabolic, featuring two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : Menaquinone-7,Ankascin 568-R

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Gnosis by Lesaffre

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Undisclosed

                          May 25, 2021

                          Lead Product(s) : Menaquinone-7,Inapplicable

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Gnosis by Lesaffre

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Aristotle University Of Thessaloniki

                          Country arrow
                          EPSC
                          Not Confirmed

                          Aristotle University Of Thessaloniki

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          May 25, 2021

                          Lead Product(s) : Menaquinone-7,Aspirin

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Sponsor : NattoPharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          National University Health System, Singapore

                          Country arrow
                          EPSC
                          Not Confirmed

                          National University Health System, Singapore

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          August 17, 2016

                          Lead Product(s) : Menaquinone-7,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : National Medical Research Council, Singapore | NattoPharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank